# Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

> **NCT06694454** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Carcinoma
- Non Small Cell Lung Cancer
- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** azacytidine
- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **DRUG:** durvalumab
- **DRUG:** cisplatin
- **DRUG:** gemcitabine
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT06694454
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2031-12-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694454, "Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06694454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*